188 related articles for article (PubMed ID: 26819748)
41. High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission.
Araujo EG; Finzel S; Englbrecht M; Schreiber DA; Faustini F; Hueber A; Nas K; Rech J; Schett G
Ann Rheum Dis; 2015 Apr; 74(4):655-60. PubMed ID: 24336010
[TBL] [Abstract][Full Text] [Related]
42. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.
Hellgren K; Smedby KE; Backlin C; Sundstrom C; Feltelius N; Eriksson JK; Baecklund E; Askling J
Arthritis Rheumatol; 2014 May; 66(5):1282-90. PubMed ID: 24782185
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.
Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R;
Ann Rheum Dis; 2015 May; 74(5):890-6. PubMed ID: 24431398
[TBL] [Abstract][Full Text] [Related]
44. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.
Chang CY; Meyer RM; Reiff AO
Arthritis Care Res (Hoboken); 2015 May; 67(5):658-66. PubMed ID: 25220674
[TBL] [Abstract][Full Text] [Related]
45. Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis.
Fleischmann R; Tongbram V; van Vollenhoven R; Tang DH; Chung J; Collier D; Urs S; Ndirangu K; Wells G; Pope J
RMD Open; 2017; 3(1):e000371. PubMed ID: 28123782
[TBL] [Abstract][Full Text] [Related]
46. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kalstad S; Rødevand E; Mikkelsen K; Lexberg AS; Kvien TK
Ann Rheum Dis; 2013 Nov; 72(11):1840-4. PubMed ID: 23562987
[TBL] [Abstract][Full Text] [Related]
47. Maintenance of Sustained Low Disease Activity or Remission in Patients With Rheumatoid Arthritis Treated With Etanercept Monotherapy: Results from the Corrona Registry.
Pappas DA; Shan Y; Lesperance T; Kricorian G; Karis E; Rebello S; Hua W; Accortt NA; Stryker S
ACR Open Rheumatol; 2020 Oct; 2(10):588-594. PubMed ID: 32990361
[TBL] [Abstract][Full Text] [Related]
48. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
Jørgensen TS; Kristensen LE; Christensen R; Bliddal H; Lorenzen T; Hansen MS; Østergaard M; Jensen J; Zanjani L; Laursen T; Butt S; Dam MY; Lindegaard HM; Espesen J; Hendricks O; Kumar P; Kincses A; Larsen LH; Andersen M; Næser EK; Jensen DV; Grydehøj J; Unger B; Dufour N; Sørensen V; Vildhøj S; Hansen IM; Raun J; Krogh NS; Hetland ML
Rheumatology (Oxford); 2015 Dec; 54(12):2156-65. PubMed ID: 26175471
[TBL] [Abstract][Full Text] [Related]
49. Changes in musculoskeletal disease activity and patient-reported outcomes in patients with psoriatic arthritis treated with ixekizumab: results from a real-world US cohort.
Tillett W; Birt J; Cavanaugh C; Jung Y; Vadhariya A; Ross S; Paulus J; Lubrano E
Front Med (Lausanne); 2023; 10():1184028. PubMed ID: 37415769
[TBL] [Abstract][Full Text] [Related]
50. Patient outcomes improve when a molecular signature test guides treatment decision-making in rheumatoid arthritis.
Curtis JR; Strand V; Golombek S; Zhang L; Wong A; Zielinski MC; Akmaev VR; Saleh A; Asgarian S; Withers JB
Expert Rev Mol Diagn; 2022 Nov; ():1-10. PubMed ID: 36305319
[TBL] [Abstract][Full Text] [Related]
51. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
Kobayakawa T; Kojima T; Takahashi N; Hayashi M; Yabe Y; Kaneko A; Shioura T; Saito K; Hirano Y; Kanayama Y; Miyake H; Asai N; Funahashi K; Hirabara S; Hanabayashi M; Asai S; Ishiguro N
Mod Rheumatol; 2015 Mar; 25(2):251-6. PubMed ID: 25211402
[TBL] [Abstract][Full Text] [Related]
52. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010.
Aga AB; Lie E; Uhlig T; Olsen IC; Wierød A; Kalstad S; Rødevand E; Mikkelsen K; Kvien TK; Haavardsholm EA
Ann Rheum Dis; 2015 Feb; 74(2):381-8. PubMed ID: 24285493
[TBL] [Abstract][Full Text] [Related]
53. Real-World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
Mease PJ; O'Brien J; Middaugh N; Kricorian G; Stryker S; Collier DH; Ogdie A
ACR Open Rheumatol; 2023 Aug; 5(8):388-398. PubMed ID: 37356824
[TBL] [Abstract][Full Text] [Related]
54. Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.
Mease PJ; Karki C; Liu M; Kavanaugh A; Ritchlin CT; Huynh DH; Palmer JB; Greenberg JD
RMD Open; 2018; 4(1):e000638. PubMed ID: 29707232
[TBL] [Abstract][Full Text] [Related]
55. Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line.
Svedbom A; Dalén J; Black CM; Kachroo S
Patient Prefer Adherence; 2017; 11():95-106. PubMed ID: 28144130
[TBL] [Abstract][Full Text] [Related]
56. Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?
Ramiro S; Landewé R; van der Heijde D; Harrison D; Collier D; Michaud K
RMD Open; 2015; 1(1):e000155. PubMed ID: 26629366
[TBL] [Abstract][Full Text] [Related]
57. Long-term effectiveness of tumour necrosis factor-α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study.
Clunie G; McInnes IB; Barkham N; Marzo-Ortega H; Patel Y; Gough A; Packham J; Kyle S; Kirkham B; Sheeran T; Coope H; Bishop-Bailey A; McHugh N
Rheumatol Adv Pract; 2018; 2(2):rky042. PubMed ID: 31431979
[TBL] [Abstract][Full Text] [Related]
58. Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis.
Ogdie A; Maksabedian Hernandez EJ; Shaw Y; Stolshek B; Michaud K
ACR Open Rheumatol; 2022 Nov; 4(11):935-941. PubMed ID: 35971643
[TBL] [Abstract][Full Text] [Related]
59. Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry.
Højgaard P; Glintborg B; Hetland ML; Hansen TH; Lage-Hansen PR; Petersen MH; Holland-Fischer M; Nilsson C; Loft AG; Andersen BN; Adelsten T; Jensen J; Omerovic E; Christensen R; Tarp U; Østgård R; Dreyer L
Ann Rheum Dis; 2015 Dec; 74(12):2130-6. PubMed ID: 25063827
[TBL] [Abstract][Full Text] [Related]
60. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis.
Chandran V; Shen H; Pollock RA; Pellett FJ; Carty A; Cook RJ; Gladman DD
J Rheumatol; 2013 Jun; 40(6):866-71. PubMed ID: 23637322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
